ATA-3219
- Generic Name
- ATA-3219
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 26
- Registration Number
- NCT06429800
- Locations
- 🇺🇸
Atara Biotherapeutics, Thousand Oaks, California, United States
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Phase 1
Terminated
- Conditions
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 1
- Registration Number
- NCT06256484
- Locations
- 🇺🇸
AdventHealth Cancer Institute, Orlando, Florida, United States
🇺🇸Norton Cancer Institute - Saint Matthews, Louisville, Kentucky, United States
🇺🇸Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath